Psilocybin Therapy of Psychiatric Disorders Is Not Hampered by hERG Potassium Channel–Mediated Cardiotoxicity

Psilocybin, a hallucinogen contained in “magic” mushrooms, holds great promise for the treatment of various psychiatric disorders, and early clinical trials are encouraging. Adverse cardiac events after intake of high doses of psilocybin and a trial reporting QT interval prolongation in the electroc...

Descripción completa

Detalles Bibliográficos
Autores principales: Hackl, Benjamin, Todt, Hannes, Kubista, Helmut, Hilber, Karlheinz, Koenig, Xaver
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9017764/
https://www.ncbi.nlm.nih.gov/pubmed/34871422
http://dx.doi.org/10.1093/ijnp/pyab085

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9017764/
https://www.ncbi.nlm.nih.gov/pubmed/34871422
http://dx.doi.org/10.1093/ijnp/pyab085

Ejemplares similares